MedTrace Logo

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

NCT01331083 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2023-08-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your prostate cancer. The investigators will also watch you carefully for any side effects that PX-866 might cause.

Conditions

Interventions

DRUG

PX-866

PX-866: 8mg orally taken daily

Sponsors & Collaborators

  • Oncothyreon Canada Inc.

    collaborator INDUSTRY

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Kim Chi · BCCA Vancouver Cancer Centr

  • Sebastien Hotte · Juravinski Cancer Centre at Hamilton Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-09
Primary Completion
2015-01-13
Completion
2015-11-27
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01331083 on ClinicalTrials.gov